Angiotensin converting enzyme inhibition: From viper to patient

Heart

Volumn 84, Issue SUPP, 2000, Pages

  Komajda, Michel ^a   Wimart, Marie Catherine ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ATENOLOL; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; CILAZAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FOSINOPRIL; LISINOPRIL; LOSARTAN; MOEXIPRIL; PERINDOPRIL; QUINAPRIL; RAMIPRIL; SNAKE VENOM; TRANDOLAPRIL; VASODILATOR AGENT; ZOFENOPRIL;

ACUTE HEART INFARCTION; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; HEART FAILURE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TREATMENT INDICATION; TREATMENT OUTCOME;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOMEGALY; DIABETIC NEPHROPATHIES; DIABETIC RETINOPATHY; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTENSION; KIDNEY FAILURE; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIALS; RENIN-ANGIOTENSIN SYSTEM;

EID: 0033866334     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53.
2. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-13.
3. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril prevention project (CAPPP) randomized trial. Lancet 1999;353:611-16.
4. The STOP-Hypertension-2 Study Group. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity in the Swedish trial in old patients with hypertension-2 study. Lancet 1999;354: 1751-6.
5. Elliot WJ. ALLHAT: the largest and most important clinical trial in hypertension ever done in the USA. Antihypertensive and lipid lowering to prevent heart attack trial. Am J Hypertens 1996;9(4)Pt 1:342-60.
6. Dahlof B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. A meta-analysis of 109 treatment studies. Am J Hypertens 1992;5:95-110.
7. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the co-operative north Scandinavian enalapril survival study (CONSENSUS). N Engl J Med 1987;316:1429-35.
8. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
9. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325: 303-10.
10. The ATLAS Study Group. Comparative effects of low and high doses of the angiotensin-converting-enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation 1999;100:2312-18.
11. Pfeffer MA, Braunwald E, Move LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl Med 1992; 327:669-77.
12. ISIS-4 Collaborative Group. ISIS-4: a randomized factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction. Lancet 1995;345: 669-85.
13. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994;343:1115-22.
14. Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456-62.
15. The EUCLID Study Group. Randomised placebo controlled trial of lisinopril in normotensive patients with insulin dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997;349:1787-92.
16. Locatelli F, Carbarns IR, Maschio G, et al. Long-term progression of chronic renal insufficiency in the AIPRI extension study. The angiotensin-converting-enzyme inhibition in progressive renal insufficiency study group. Kidney Int Suppl 1997;63:S63-6.
17. The GISEN Group. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997;349:1857-63.
18. Chaturvedi N, Sjolie AK, Stephenson JM, et al. Effect of lisinopril on progression of retinopathy in normo tensive people with type 1 diabetes. Lancet 1998;351:28-31.
19. Akasu M, Urata H, Kinoshita A, et al. Differences in tissue angiotensin II-forming pathways by species and organs in vitro. Hypertension 1998;32:514-20.
20. Danser A, M van Dijk, I Kroon, et al. Evidence for the functional importance of ACE-dependent in-situ angiotensin II generation in the human forearm [abstract]. Circulation 1999;100(suppl 1):548.
21. Topol E. ACE inhibitors still the drug of choice for heart failure. Lancet 1999; 354:1797.
22. Swedberg K, Pfeffer M, Granger C, Held P et al. Candesartan in heart failure - assessment of reduction in mortality and morbidity (CHARM): rationale and design. CharmProgramme Investigators. J Card Fail 1999;5:276-82.